Methods of colchicine administration
DC
First Claim
Patent Images
1. A method of administering colchicine to a patient in need thereof while concomitantly administering a second drug that is an inhibitor of P-glycoprotein 1 (P-gp) but is not an inhibitor of the cytochrome P450 3A4 isozyme (CYP3A4), wherein the second drug is propafenone, wherein the method comprises:
- (a) administering to the patient a fixed maintenance dose of colchicine in an amount of from about 0.6 to about 1.2 mg/day, for a maintenance period of a plurality of days, without administering propafenone;
(b) after step (a), administering to the patient one or more therapeutically effective doses of the second drug; and
(c) concomitantly with step (b), administering to the patient the fixed maintenance dose of colchicine of step (a) without dose reduction.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.
18 Citations
13 Claims
-
1. A method of administering colchicine to a patient in need thereof while concomitantly administering a second drug that is an inhibitor of P-glycoprotein 1 (P-gp) but is not an inhibitor of the cytochrome P450 3A4 isozyme (CYP3A4), wherein the second drug is propafenone, wherein the method comprises:
-
(a) administering to the patient a fixed maintenance dose of colchicine in an amount of from about 0.6 to about 1.2 mg/day, for a maintenance period of a plurality of days, without administering propafenone; (b) after step (a), administering to the patient one or more therapeutically effective doses of the second drug; and (c) concomitantly with step (b), administering to the patient the fixed maintenance dose of colchicine of step (a) without dose reduction. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
-
8. A method of preventing gout flares in a patient in need thereof comprising administering colchicine while concomitantly administering a second drug that is an inhibitor of P-glycoprotein 1 (P-gp) but is not an inhibitor of the cytochrome P450 3A4 isozyme (CYP3A4), wherein the second drug is propafenone, wherein the method comprises:
-
(a) administering to the patient a fixed maintenance dose of colchicine in an amount of from about 0.6 to about 1.2 mg/day, for a maintenance period of a plurality of days, without administering propafenone; (b) after step (a), administering to the patient one or more therapeutically effective doses of the second drug; and (c) concomitantly with step (b), administering to the patient the fixed maintenance dose of colchicine of step (a) without dose reduction. - View Dependent Claims (9, 10, 11, 12, 13)
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeHikma Pharmaceuticals LLC (Hikma Pharmaceuticals PLC)
-
Original AssigneeHikma Pharmaceuticals LLC (Hikma Pharmaceuticals PLC)
-
InventorsDucharme, Murray
-
Primary Examiner(s)Carter, Kendra D
-
Assistant Examiner(s)MATOS NEGRON, TAINA DEL MAR
-
Application NumberUS14/511,703Publication NumberTime in Patent Office977 DaysField of SearchNoneUS Class CurrentCPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/12 KetonesA61K 31/133 having hydroxy groups, e.g....A61K 31/138 Aryloxyalkylamines, e.g. pr...A61K 31/165 having aromatic rings, e.g....A61K 31/4164 1,3-DiazolesA61K 31/4196 1,2,4-TriazolesA61K 31/506 not condensed and containin...
